secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273107
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma reports Q3 net loss $51.2M; neffy net product revenue $31.3M
-----------------------------------------------------------------------

- Q3 2025 total revenue $32.5M, including $31.3M neffy U.S. net product revenue; net loss $51.2M ($0.52/share).
- SG&A expenses $74.8M, driven by DTC campaign; cash position $288.2M, including $100M term loan draw.
- Over 18,000 HCPs have prescribed neffy (86% increase from Aug 2025); consumer awareness rose from 20% to 56%.
- Japan approval for neffy in Sep 2025; U.K. launch of EUR neffy in Oct 2025; EU approval for 1 mg expected H1 2026.
- Phase 2b urticaria trial enrolling; topline data anticipated mid-2026; company targets cash-flow breakeven.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525273107/0001193125-25-273107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312525273107/spry-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer